Ardigen and VERAXA Biotech have announced a collaboration aimed at enhancing drug discovery through AI technologies, specifically targeting cancer therapies.
This partnership will leverage Ardigen's expertise in AI and computational biology to support VERAXA's BiTAC pipeline, which focuses on T cell engagers (TCEs) and antibody-drug conjugates (ADCs). By utilizing AI-enabled tools, the collaboration aims to optimize the selection of cancer target pairs, thereby improving therapeutic designs while minimizing toxicities often associated with current modalities.
VERAXA's approach involves a unique Boolean “AND-gate” logic that requires two distinct targets to be co-expressed on cancer cells for activation. This strategy is intended to enhance the therapeutic window, reducing the risk of damaging healthy tissues. The integration of extensive preclinical and clinical data through AI analysis will facilitate the identification of more effective dual-target combinations, ultimately refining the development process for these innovative therapies.
The collaboration signifies a strategic move towards applying AI in precision oncology, with both companies expressing optimism about the potential for improved success rates and product profiles in cancer treatment. As the industry continues to evolve, this partnership could set a precedent for future AI-driven advancements in drug discovery.